## CRL: Charles River Laboratories Inte - XLV: Healthcare

### Executive Summary

VALUE thesis: PEG 0.14 indicates fundamental undervaluation. Consistent execution (4/4 quarters beat estimates). Caution: declining volume (42% of avg).

- **Horizon:** 20-60 days (position)
- **Risk Profile:** Lower - fundamental undervaluation
- **Stop Type:** Fixed 2xATR ($163.67)
- **If Wrong:** Exit if fundamentals deteriorate or stop hit
- **Invalidation:** PEG > 1.5 or earnings miss

### News

- **Articles:** 7
- **Sentiment:** Neutral (Bullish: 0, Bearish: 0)

**1. Charles River Laboratories to Present at Evercore Healthcare Conference**
- Source: Business Wire | 20251201T132134 | Somewhat-Bullish | Relevance: 99%
- Charles River Laboratories International, Inc. announced it will present at the Evercore 8th Annual Healthcare Conference on December 3rd at 10:00 a.m. ET. Management will discuss the company's strategic focus, business developments, and recent trends. A live webcast and replay will be available on the Investor Relations section of the Charles River website.

**2. HALPER SADEH LLC ENCOURAGES CHARLES RIVER LABORATORIES INTERNATIONAL, INC. SHAREHOLDERS TO CONTACT THE FIRM TO DISCUSS THEIR RIGHTS**
- Source: NEWS10 ABC | 20251201T154200 | Neutral | Relevance: 99%
- Halper Sadeh LLC, an investor rights law firm, is investigating potential breaches of fiduciary duties by officers and directors of Charles River Laboratories International, Inc. The firm encourages shareholders, especially long-term ones, to contact them to discuss their legal rights and options, which could include corporate governance reforms or financial awards. Halper Sadeh LLC operates on a contingent fee basis and stresses the importance of shareholder involvement in improving company practices and enhancing value.

**3. HALPER SADEH LLC ENCOURAGES CHARLES RIVER LABORATORIES INTERNATIONAL, INC. SHAREHOLDERS TO CONTACT THE FIRM TO DISCUSS THEIR RIGHTS**
- Source: WBOY.com | 20251201T154200 | Neutral | Relevance: 98%
- Halper Sadeh LLC, an investor rights law firm, is investigating whether officers and directors of Charles River Laboratories International, Inc. (NYSE: CRL) breached their fiduciary duties to shareholders. The firm encourages current Charles River stock owners, who are long-term shareholders, to contact them to discuss potential corporate governance reforms, the return of funds to the company, or other relief. Halper Sadeh LLC offers to handle actions on a contingent fee basis, emphasizing that shareholder involvement can improve company policies and enhance shareholder value.

**4. HALPER SADEH LLC ENCOURAGES CHARLES RIVER LABORATORIES INTERNATIONAL, INC. SHAREHOLDERS TO CONTACT THE FIRM TO DISCUSS THEIR RIGHTS**
- Source: PR Newswire | 20251201T204200 | Neutral | Relevance: 98%
- Halper Sadeh LLC, an investor rights law firm, is investigating whether officers and directors of Charles River Laboratories International, Inc. (NYSE: CRL) breached their fiduciary duties to shareholders. The firm encourages current Charles River shareholders, especially long-term ones, to contact them to discuss potential rights, including corporate governance reforms, return of funds, or financial incentive awards. This action would be handled on a contingent fee basis, emphasizing that shareholder involvement can enhance corporate transparency and shareholder value.

**5. HALPER SADEH LLC ENCOURAGES CHARLES RIVER LABORATORIES INTERNATIONAL, INC. SHAREHOLDERS TO CONTACT THE FIRM TO DISCUSS THEIR RIGHTS**
- Source: Morningstar | 20251201T204200 | Neutral | Relevance: 98%
- Halper Sadeh LLC, an investor rights law firm, is investigating whether certain officers and directors of Charles River Laboratories International, Inc. (NYSE: CRL) breached their fiduciary duties to shareholders. The firm encourages long-term shareholders to contact them to discuss legal rights and options, which may include corporate governance reforms, the return of funds to the company, or a financial incentive award. Halper Sadeh LLC handles these actions on a contingent fee basis, emphasizing that shareholder involvement can improve company policies and enhance shareholder value.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 1, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-11-11 | Morgan Stanley | $185 | $170 | +9% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-11-11 | Morgan Stanley | main | Equal-Weight |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_BUYING** |
| Buys | 1 ($0.50M) |
| Sells | 0 ($0.00M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 47.8% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 7 / 3 |

**Top Holders:**
- Vanguard Group Inc: 11.9% (+0.5%)
- Blackrock Inc.: 7.8% (+5.5%)
- Wellington Managemen: 6.5% (-15.3%)
- Allspring Global Inv: 4.4% (-4.9%)
- State Street Corpora: 3.7% (-1.5%)

### Key Risks

1. Market regime shift could impact high-beta names disproportionately.
2. Sector rotation risk if leadership changes from current market theme.
3. Earnings execution risk on next quarterly report.

### Catalysts

- Momentum building: MRS_20 improving +1.5% over 5 days suggests accumulation.
- Broader market risk-on sentiment could lift quality names.

### Fundamentals

PEG ratio 0.14 indicates undervaluation relative to growth. Forward P/E 16.1x stretched relative to 7% growth. Analyst sentiment positive (1 raises, avg +9%). Institutional flow bullish (7 buying vs 3 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $9.6B |
| Beta | 1.64 |
| 52W Range | $91.86 - $200.10 |
| Short Interest | 6.0% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 0.14 |
| Forward P/E | 16.1 |
| Current P/E | 17.2 |
| YoY Growth | 6.8% |
| EPS Direction | STABLE |

### Technicals

MRS_20 strengthening from 0.6% to 2.1% (+1.5% in 5 days), confirming momentum buildup. Below STRENGTH zone by 1.9pp (needs >4.0% for momentum thesis). MRS_5 (-0.7%) diverging from MRS_20 - short-term weakness emerging. AM_20 at 3.2% shows strong absolute momentum above own 20MA. Full SMA alignment bullish (above 20/50/200 SMAs). MACD histogram positive (1.16), confirming momentum. RSI neutral at 55. Volume at 42% of 20MA suggests lack of conviction.

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | 2.15% (CS: 74) | Neutral |
| RSI_14 | 55.0 | Neutral |
| MACD Histogram | 1.16 | Bullish |
| vs SMA20 | 1.032x | Above |
| vs SMA50 | 1.026x | Above |
| vs SMA200 | 1.133x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** VALUE

### Trade Setup

- **Entry:** $176.09
- **Stop Loss:** $163.67 (7.1% risk)
- **Target:** $200.93 (R:R method)
- **Risk/Reward:** 2.00:1
- **Target Reasoning:** VALUE thesis targets 2.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 60
- **Position Value:** $10,565.40
- **Portfolio %:** 10.57%
- **Risk Dollars:** $750.00
- **Risk Per Trade:** 0.75%
- **Modifiers:** L1 100% | L2 75% | Combined 0.75x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.00x |
| L2 Sector | WEAKENING (Zone B) | 0.75x |

### Earnings

**Next:** 2026-02-18 (Est: $2.34)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $2.34 | $2.43 | +3.9% |
| 2025Q2 | $2.55 | $3.12 | +22.4% |
| 2025Q1 | $2.07 | $2.34 | +12.8% |
| 2024Q4 | $2.53 | $2.66 | +5.2% |

---
*RULE-based L3 | 2026-01-06 16:36 | MRS_20*